HCV Treatment
CROI 2011: Interactions of HIV Meds with HCV drugs Telaprevir and Boceprevir
- Details
- Category: Approved HCV Drugs
- Published on Tuesday, 22 March 2011 00:00
- Written by Liz Highleyman
New HCV antiviral drugs can interact with some antiretroviral drugs for HIV, but others are not affected and HIV/HCV coinfected patients can be treated successfully with minimal dose adjustments.
CROI 2011: HCV Protease Inhibitor Boceprevir Improves Response for Treatment-Naive and Non-responders
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 15 March 2011 12:37
- Written by Liz Highleyman
Merck's investigational hepatitis C virus (HCV) protease inhibitor boceprevir improved sustained response rates when combined with pegylated interferon plus ribavirin in both previously untreated patients and those who were non-responders or relapsers after prior therapy, according to 2 Phase 3 studies presented at the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) this month in Boston. 
HCV Polymerase Inhibitor INX-189 Gets FDA Fast-Track Status, TMC649128 Enters Phase 1a Trial
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 07 March 2011 21:01
- Written by Liz Highleyman
The development of direct-acting antiviral agents active against hepatitis C virus (HCV) continues at a rapid pace. Two pharmaceutical companies this month announced progress in the development of investigational HCV polymerase inhibitors. Inhibitex said that it's candidate INX-189 has received "Fast Track" designation from the U.S. Food and Drug Administration (FDA), which allows for accelerated review and approval. Sweden's Medivir announced the start of the first human trial of its drug, TMC649128, in healthy volunteers.
Telaprevir Improves Treatment Outcomes for HIV/HCV Coinfected People
- Details
- Category: HCV Treatment
- Published on Monday, 07 March 2011 21:05
- Written by Liz Highleyman
The experimental hepatitis C virus (HCV) protease inhibitor telaprevir, combined with pegyalted interferon plus ribavirin, reduced HCV viral load to undetectable levels in about 70% of HIV positive patients at weeks 4 and 12 in the first study of the drug in HIV/HCV coinfected people. Based on these eagerly awaited Phase 2 results, presented this week at the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) in Boston, Vertex Pharmaceuticals plans to start a Phase 3 coinfection study later this year. 
12- Versus 24-week Treatment with Pegylated Interferon plus Ribavirin for Genotype 2 or 3 Chronic Hepatitis C Patients
- Details
- Category: HCV Treatment
- Published on Monday, 07 March 2011 13:03
- Written by HIVandHepatitis.com
In an effort to reduce the cost and side effects of treatment for chronic hepatitis C virus (HCV) infection, researchers have explored shorter courses of pegylated interferon plus ribavirin for individuals with easier-to-treat HCV genotypes 2 or 3. The standard course of therapy for patients with these genotypes is 24 weeks (compared with 48 weeks for those with genotype 1). To date, previous trials looking at the efficacy of treatment durations shorter than 24 weeks for genotype 2 or 3 patients have yielded discordant results.
In the present study, reported in the June 2008 issue of Hepatology, Scandinavian researchers conducted a Phase III trial to compare the efficacy of 12 or 24 weeks of treatment, and to identify patients suitable for short-term therapy.
More Articles...
- DDW 2008: Pegylated Interferon (Pegasys) Continues to Suppress HBV, Adding Adefovir (Hepsera) Provides No Extra Benefit
- Anadys Starts Phase 2b Study of HCV Polymerase Inhibitor ANA598
- Drinking More Coffee Linked to Improved Response to Hepatitis C Treatment
- Boceprevir Improves Response to Interferon-based Therapy and Allows Many Patients to Reduce Duration
Web Design and Development by